Somalogic Inc

F:76X0

SomaLogic, Inc. is a commercial-stage proteomics company, which built an integrated proteomics platform for robust, high throughput proteomics analysis, research and clinical applications. The company is headquartered in New York City, New York and currently employs 320 full-time employees. The company went IPO on 2021-02-23. The company develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein-binding reagents that are specific for their cognate protein. The company offers SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. Its products include SomaScan Assay, SomaSignal Tests, SomaScan Panels, and SOMAmer Reagents. SomaScan Assay is utilized for Research Use Only (RUO) applications. Its SomaScan Assay measures approximately 7,000 protein target measurements in a single sample. SomaSignal Tests are available as laboratory developed tests (LDT) for use in obtaining proteomics information from patients and monitoring patients’ physiological states, among others. SomaScan Panels consists of two categories: fixed panels and custom panels. The company offers drug development, analysis of clinical trial and new human biology insights.